🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "huge turning point" in the battle against drug-resistant strains of the infection, according to researchers.

An International Health Concern

Gonorrhoea infections are escalating around the world, with data suggesting over 82 million new cases annually. Especially elevated rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune advancement in the face of rising global incidence, the spread of superbugs and the extremely scarce treatment choices at this time.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program found that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Treatment Options Secure Clearance

Zoliflodacin, alternatively called a brand name, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Experts anticipate that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This treatment, which is employed against UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This milestone marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Testing Data and Global Access

According to results detailed in a major medical journal, the new drug eradicated the vast majority of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which combines an injection and a pill. The trial included nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the authority to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors treating patients have voiced optimism. Access to a one-pill regimen such as this is described as a "game-changer" for public health efforts. This is deemed vital to reduce the burden of the illness for people and to prevent the spread of untreatable gonorrhoea around the world.